According to ContraFect's latest financial reports the company's current earnings (TTM) are -$24.14 M. In 2022 the company made an earning of -$65.16 M a decrease over its 2021 earnings that were of -$20.29 M.The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Year | Earnings | Change |
---|---|---|
2023 (TTM) | -$24.14 M | -62.95% |
2022 | -$65.16 M | 221.24% |
2021 | -$20.29 M | -27.96% |
2020 | -$28.16 M | 120.06% |
2019 | -$12.8 M | -66.05% |
2018 | -$37.69 M | 142.85% |
2017 | -$15.52 M | -45.63% |
2016 | -$28.54 M | 13.6% |
2015 | -$25.13 M | -16.68% |
2014 | -$30.15 M | 27.64% |
2013 | -$23.63 M |
Company | Earnings | Earnings differencediff. | Country |
---|---|---|---|
Viking Therapeutics
VKTX | -$93.72 M | 288.27% | ๐บ๐ธ USA |
Recro Pharma
REPH | $3.76 M | -115.59% | ๐บ๐ธ USA |
Prometheus Biosciences RXDX | -$0.17 B | 566.82% | ๐บ๐ธ USA |